Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Strathspey Crown Announces Issuance of US Patent for Gene Modulation of Cellular Structures and DNA

Strathspey Crown LLC
Posted on: 06 Dec 18
Strathspey Crown Announces Issuance of US Patent for Gene Modulation of Cellular Structures and DNA

PR Newswire

NEWPORT BEACH, Calif., Dec. 6, 2018

NEWPORT BEACH, Calif., Dec. 6, 2018 /PRNewswire/ -- Strathspey Crown LLC (SC), a growth equity firm specializing in healthcare and lifestyle technology, today announced that the United States Patent and Trademark Office has issued US Patent 10,004,661 (Inventors: Robert Edward Grant, Matthew Case and Todd Mirzai, MD) covering the system and method for titrating in vivo cellular reaction and genetic expression using varying oscillation frequencies. This patent is being added to the rapidly expanding portfolio at Strathspey Crown of ground-breaking patents that target and alter the genetic expression of specific cells.

The primary claim of US Patent 10,004,661 is the system and method for titrating in vivo cellular reaction and gene expression using sound and light frequencies. A sensor is placed via an epidermal or implantable patch which sends data of the specific cell or tissue to a computer which compares the current data to the desired phenotype. The computer then determines the proper levels of oscillating frequencies based on pre-set parameters. All data from the cell is monitored and adjusted until the cellular reactions result in the desired phenotypic differentiation of the target tissue.

Strathspey Crown LLC Chairman and lead co-inventor, Robert E. Grant commented, "We are thrilled to further expand our intellectual property portfolio as we advance our understanding of gene mutation and modulation utilizing oscillating frequencies. The impact that gene modulation will likely have on the targeted and ongoing treatment of disease is profound. As a firm focused on products, processes and technologies that deliver lifestyle enhancement and significantly extending life, these patents will be put to good use."

Strathspey Crown is devoted to the advancement of science and technology that will revolutionize the treatment and prevention of varying genetic expression. Strathspey Crown presently has several patent applications in pending status with the US Patent and Trademark office, each addressing significant future market segments across medicine, genetic expression, as well as, miniature implantable smart-ocular technologies integrating cameras, an LED display, wireless connectivity and solar recharging ability, including augmented reality-ready ocular implantable technologies.

About Strathspey Crown LLC: Strathspey Crown is a growth equity firm whose subsidiaries specialize in fields across lifestyle healthcare, clean energy, and financial technology. For more information, please visit www.strathspeycrown.com.  

Strathspey Crown LLC Press Contact
Tel: +1-949-260-1700

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/strathspey-crown-announces-issuance-of-us-patent-for-gene-modulation-of-cellular-structures-and-dna-300761125.html

SOURCE Strathspey Crown LLC

PR Newswire
www.prnewswire.com

Last updated on: 06/12/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.